Citadel Advisors
ZYNE

Citadel Advisors’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Citadel Advisors’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed -$33 – 15452
2023
Q2 		$33 Buy
+100
New +$36 ﹤0.01% 14240
2023
Q1 		– Sell
-8,100
Closed -$4.29K – 15869
2022
Q4 		$4.29K Sell
8,100
-6,300
-44% -$4K ﹤0.01% 14109
2022
Q3 		$11K Sell
14,400
-2,200
-13% -$2.5K ﹤0.01% 12262
2022
Q2 		$19K Sell
16,600
-1,600
-9% -$2.04K ﹤0.01% 12434
2022
Q1 		$37K Sell
18,200
-4,400
-19% -$10.5K ﹤0.01% 12995
2021
Q4 		$65K Sell
22,600
-8,600
-28% -$31.8K ﹤0.01% 13092
2021
Q3 		$132K Sell
31,200
-10,300
-25% -$45.9K ﹤0.01% 12534
2021
Q2 		$220K Sell
41,500
-66,200
-61% -$318K ﹤0.01% 11959
2021
Q1 		$501K Buy
107,700
+39,800
+59% +$180K ﹤0.01% 9680
2020
Q4 		$224K Buy
67,900
+13,400
+25% +$50.9K ﹤0.01% 9568
2020
Q3 		$180K Sell
54,500
-69,900
-56% -$257K ﹤0.01% 8890
2020
Q2 		$419K Buy
124,400
+82,500
+197% +$390K ﹤0.01% 7374
2020
Q1 		$160K Buy
41,900
+8,200
+24% +$38.1K ﹤0.01% 8229
2019
Q4 		$204K Sell
33,700
-4,100
-11% -$28K ﹤0.01% 8154
2019
Q3 		$286K Sell
37,800
-18,100
-32% -$204K ﹤0.01% 7619
2019
Q2 		$757K Buy
55,900
+27,500
+97% +$317K ﹤0.01% 6158
2019
Q1 		$154K Sell
28,400
-15,400
-35% -$74.9K ﹤0.01% 8375
2018
Q4 		$130K Sell
43,800
-73,000
-63% -$400K ﹤0.01% 8131
2018
Q3 		$953K Buy
116,800
+12,100
+12% +$92.9K ﹤0.01% 5642
2018
Q2 		$1.02M Buy
104,700
+71,900
+219% +$737K ﹤0.01% 5180
2018
Q1 		$285K Buy
+32,800
New +$354K ﹤0.01% 6834
2017
Q4 		– Sell
-39,600
Closed -$331K – 8573
2017
Q3 		$331K Sell
39,600
-9,300
-19% -$98.3K ﹤0.01% 5912
2017
Q2 		$830K Buy
48,900
+7,800
+19% +$155K ﹤0.01% 4368
2017
Q1 		$826K Buy
+41,100
New +$817K ﹤0.01% 4279
2016
Q4 		– Sell
-18,900
Closed -$247K – 8015
2016
Q3 		$247K Buy
+18,900
New +$180K ﹤0.01% 5990

Other funds holding ZYNE

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
CM
Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citadel Advisors's ZYNE Position: Q1 2023 in Review

Citadel Advisors sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2023, closing a stake of 17,471 shares — an estimated $9.21K sold.

Citadel Advisors first reported a position in ZYNE in Q3 2016 and held it in 16 quarters. The position peaked at $7.78M in Q2 2017. 44 funds tracked by Wall St. Rank hold ZYNE as of Q1 2023.

  • Citadel Advisors reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 17,471 Zynerba Pharmaceuticals, Inc shares in Q1 2023, an estimated $9.21K.
  • Citadel Advisors first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 16 quarters.
  • Citadel Advisors's Zynerba Pharmaceuticals, Inc position peaked at $7.78M in Q2 2017.
  • 44 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.